Shanshan Pei,Ian T Shelton,Austin E Gillen,Brett M Stevens,Maura Gasparetto,Yanan Wang,Lina Liu,Jun Liu,Tonya M Brunetti,Krysta Engel,Sarah Staggs,William Showers,Anagha Inguva Sheth,Maria L Amaya,Mohammad Minhajuddin,Amanda Winters,Sweta B Patel,Hunter Tolison,Anna E Krug,Tracy N Young,Jeffrey Schowinsky,Christine M McMahon,Clayton A Smith,Daniel A Pollyea,Craig T Jordan,Ian T. Shelton,Austin E. Gillen,Brett M. Stevens,Tonya M. Brunetti,Anagha Inguva. Sheth,Maria L. Amaya,Sweta B. Patel,Anna E. Krug,Tracy N. Young,Christine M. McMahon,Clayton A. Smith,Daniel A. Pollyea,Craig T. Jordan

Abstract:The BCL-2 inhibitor venetoclax has recently emerged as an important component of acute myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously unrecognized form of pathogenesis characterized by monocytic disease progression. We demonstrate that this form of disease arises from a fundamentally different type of leukemia stem cell (LSC), which we designate as monocytic LSC (m-LSC), that is developmentally and clinically distinct from the more well-described primitive LSC (p-LSC). The m-LSC is distinguished by a unique immunophenotype (CD34-, CD4+, CD11b-, CD14-, CD36-), unique transcriptional state, reliance on purine metabolism, and selective sensitivity to cladribine. Critically, in some instances m-LSC and p-LSC subtypes can co-reside in the same AML patient and simultaneously contribute to overall tumor biology. Thus, our findings demonstrate that LSC heterogeneity has direct clinical significance and highlights the need to distinguish and target m-LSCs as a means to improve clinical outcomes with venetoclax-based regimens.

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy